When to Take Lokelma in a Dialysis Patient
In patients on chronic hemodialysis, administer Lokelma (sodium zirconium cyclosilicate) once daily on non-dialysis days only. 1
Dosing Schedule
Initial Dosing
- Start with 5 g once daily on non-dialysis days for most hemodialysis patients with hyperkalemia 1
- Consider 10 g once daily on non-dialysis days if serum potassium is greater than 6.5 mEq/L 1
Key Timing Principle
The critical point is that Lokelma should never be given on dialysis days—only on the days between dialysis sessions. This dosing strategy was specifically validated in the DIALIZE trial, which demonstrated that once-daily SZC on non-dialysis days effectively maintained normal predialysis serum potassium levels over 8 weeks in ESRD patients 2.
Monitoring and Dose Adjustment
When to Check Potassium
- Monitor pre-dialysis serum potassium after the long inter-dialytic interval (typically the Monday or Tuesday session after the weekend gap) 1
- Assess potassium one week after initiation and after each dose adjustment 1
Dose Titration Algorithm
- Maintenance dose range: 5 g to 15 g once daily on non-dialysis days 1
- Adjust in 5 g increments based on pre-dialysis potassium values after the long inter-dialytic interval
- Discontinue or decrease dose if:
- Serum potassium falls below target range based on pre-dialysis value after long inter-dialytic interval
- Patient develops clinically significant hypokalemia 1
Administration Details
Timing Relative to Other Medications
Separate Lokelma from other oral medications by at least 2 hours (either 2 hours before or 2 hours after) because it can bind other drugs and reduce their absorption 1
Preparation
- Mix entire packet contents in approximately 3 tablespoons of water
- Stir well and drink immediately
- Rinse glass and drink again to ensure full dose administration 1
Clinical Evidence Supporting This Approach
The DIALIZE study specifically evaluated this non-dialysis day dosing strategy in 196 hemodialysis patients and found that 41.2% of patients receiving SZC maintained target potassium levels (4.0-5.0 mmol/L) during at least 3 of 4 treatments after the long inter-dialytic interval, compared to only 1.0% with placebo 3. More recent data from 2026 confirms this approach reduces pre-dialysis potassium by approximately 0.36 mmol/L with good tolerability 4.
Important Safety Considerations
Volume Status
Despite containing approximately 400 mg sodium per 5 g dose, SZC does not appear to cause clinically significant volume expansion in hemodialysis patients. Post-hoc analysis of the DIALIZE-Outcomes trial showed no difference in inter-dialytic weight gain between SZC and placebo groups 5. However, remain vigilant for edema, particularly in patients prone to fluid overload.
Hypokalemia Risk
Hemodialysis patients may be particularly vulnerable to hypokalemia during acute illnesses that decrease oral intake or cause diarrhea 1. Consider temporarily holding or reducing the dose during such episodes. Mild hypokalemia (3.0-3.5 mmol/L) occurred in approximately 8.6% of patients in recent trials, but severe hypokalemia (<3.0 mmol/L) was rare 4.
Gastrointestinal Effects
Constipation occurs in approximately 5-7% of patients 4, 6. This is generally mild but important to monitor given the dialysis population's baseline constipation risk.
Common Pitfalls to Avoid
- Never give Lokelma on dialysis days—dialysis itself removes potassium, and combining both could cause dangerous hypokalemia
- Don't use Lokelma for emergency hyperkalemia treatment—it has a delayed onset of action and is not appropriate for life-threatening hyperkalemia 1
- Don't forget to separate from other medications—the 2-hour window is essential to prevent drug binding
- Don't rely solely on random potassium checks—always use the pre-dialysis value after the long inter-dialytic interval for dose adjustments
This non-dialysis day dosing strategy represents a paradigm shift from older potassium binders and is supported by both FDA labeling and high-quality clinical trial evidence specifically in the hemodialysis population 1, 3.